Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Casi Phrmactcls Inc (CASI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 371,631
  • Shares Outstanding, K 95,290
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,770 K
  • 36-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.08
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.13 +26.20%
on 11/12/18
5.20 -24.04%
on 12/03/18
+0.52 (+15.16%)
since 11/09/18
3-Month
2.73 +44.69%
on 10/26/18
6.72 -41.22%
on 09/12/18
-2.74 (-40.96%)
since 09/11/18
52-Week
2.55 +55.21%
on 12/12/17
8.89 -55.57%
on 08/13/18
+0.60 (+17.91%)
since 12/11/17

Most Recent Stories

More News
The 4 Healthcare Stocks To Watch On Monday

CORAL GABLES, FL / ACCESSWIRE / December 3, 2018 / Attention on has continued to accelerate this quarter. This has been especially true when it comes to the companies within the health tech and med tech...

TDOC : 54.47 (+4.07%)
PHGI.CN : 1.020 (+5.15%)
KPTI : 10.23 (+1.29%)
PHGRF : 0.7660 (+7.27%)
CASI : 3.92 (+0.51%)
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 3.92 (+0.51%)
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc....

DERM : 10.72 (-1.02%)
MDGL : 113.12 (+0.20%)
ESGR : 173.30 (+0.30%)
CASI : 3.92 (+0.51%)
KALU : 91.84 (+1.59%)
BKNG : 1,856.82 (+1.69%)
CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 3.92 (+0.51%)
CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 3.92 (+0.51%)
Today's Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences

NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Biotech stocks CASI Pharmaceuticals and Therapix Biosciences were both seeing big gains on acquisition news. CASI has acquired a U.S. FDA-approved abbreviated...

FSDDF : 0.2300 (-3.73%)
CASI : 3.92 (+0.51%)
Detailed Research: Economic Perspectives on Beacon Roofing Supply, Rowan Companies, CASI Pharmaceuticals, LivePerson, Impinj, and Tredegar -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Beacon Roofing Supply, Inc....

RDC : 11.09 (-0.98%)
BECN : 32.99 (+0.89%)
TG : 16.28 (+0.12%)
PI : 18.05 (+1.69%)
CASI : 3.92 (+0.51%)
LPSN : 19.32 (-0.21%)
CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 3.92 (+0.51%)
CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 3.92 (+0.51%)
CASI Pharmaceuticals Announces $48.5 Million Private Placement

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...

CASI : 3.92 (+0.51%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade CASI with:

Business Summary

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic...

See More

Key Turning Points

2nd Resistance Point 4.11
1st Resistance Point 4.01
Last Price 3.92
1st Support Level 3.77
2nd Support Level 3.63

See More

52-Week High 8.89
Fibonacci 61.8% 6.47
Fibonacci 50% 5.72
Fibonacci 38.2% 4.97
Last Price 3.92
52-Week Low 2.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar